12-64752752-C-T

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BA1

The NM_002076.4(GNS):​c.198G>A​(p.Pro66Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.611 in 1,443,948 control chromosomes in the GnomAD database, including 277,416 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Synonymous variant affecting the same amino acid position (i.e. P66P) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.70 ( 38282 hom., cov: 32)
Exomes 𝑓: 0.60 ( 239134 hom. )

Consequence

GNS
NM_002076.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:14

Conservation

PhyloP100: -0.442

Publications

24 publications found
Variant links:
Genes affected
GNS (HGNC:4422): (glucosamine (N-acetyl)-6-sulfatase) The product of this gene is a lysosomal enzyme found in all cells. It is involved in the catabolism of heparin, heparan sulphate, and keratan sulphate. Deficiency of this enzyme results in the accumulation of undegraded substrate and the lysosomal storage disorder mucopolysaccharidosis type IIID (Sanfilippo D syndrome). Mucopolysaccharidosis type IIID is the least common of the four subtypes of Sanfilippo syndrome. [provided by RefSeq, Jul 2008]
GNS Gene-Disease associations (from GenCC):
  • mucopolysaccharidosis type 3D
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, G2P, ClinGen, Labcorp Genetics (formerly Invitae), Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.43).
BP6
Variant 12-64752752-C-T is Benign according to our data. Variant chr12-64752752-C-T is described in ClinVar as Benign. ClinVar VariationId is 94029.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-0.442 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.896 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GNSNM_002076.4 linkc.198G>A p.Pro66Pro synonymous_variant Exon 2 of 14 ENST00000258145.8 NP_002067.1 P15586-1A0A024RBC5Q7Z3X3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GNSENST00000258145.8 linkc.198G>A p.Pro66Pro synonymous_variant Exon 2 of 14 1 NM_002076.4 ENSP00000258145.3 P15586-1

Frequencies

GnomAD3 genomes
AF:
0.695
AC:
105697
AN:
152032
Hom.:
38235
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.904
Gnomad AMI
AF:
0.487
Gnomad AMR
AF:
0.619
Gnomad ASJ
AF:
0.503
Gnomad EAS
AF:
0.879
Gnomad SAS
AF:
0.680
Gnomad FIN
AF:
0.628
Gnomad MID
AF:
0.554
Gnomad NFE
AF:
0.597
Gnomad OTH
AF:
0.661
GnomAD2 exomes
AF:
0.641
AC:
157726
AN:
245972
AF XY:
0.638
show subpopulations
Gnomad AFR exome
AF:
0.912
Gnomad AMR exome
AF:
0.565
Gnomad ASJ exome
AF:
0.505
Gnomad EAS exome
AF:
0.878
Gnomad FIN exome
AF:
0.636
Gnomad NFE exome
AF:
0.596
Gnomad OTH exome
AF:
0.610
GnomAD4 exome
AF:
0.602
AC:
777176
AN:
1291798
Hom.:
239134
Cov.:
22
AF XY:
0.604
AC XY:
393305
AN XY:
650962
show subpopulations
African (AFR)
AF:
0.908
AC:
26603
AN:
29290
American (AMR)
AF:
0.571
AC:
25180
AN:
44112
Ashkenazi Jewish (ASJ)
AF:
0.509
AC:
12664
AN:
24888
East Asian (EAS)
AF:
0.870
AC:
33728
AN:
38754
South Asian (SAS)
AF:
0.662
AC:
54453
AN:
82290
European-Finnish (FIN)
AF:
0.634
AC:
33597
AN:
52990
Middle Eastern (MID)
AF:
0.573
AC:
3120
AN:
5444
European-Non Finnish (NFE)
AF:
0.578
AC:
554185
AN:
959352
Other (OTH)
AF:
0.615
AC:
33646
AN:
54678
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.444
Heterozygous variant carriers
0
13128
26256
39384
52512
65640
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
14352
28704
43056
57408
71760
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.695
AC:
105795
AN:
152150
Hom.:
38282
Cov.:
32
AF XY:
0.696
AC XY:
51742
AN XY:
74372
show subpopulations
African (AFR)
AF:
0.904
AC:
37535
AN:
41534
American (AMR)
AF:
0.618
AC:
9454
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
0.503
AC:
1745
AN:
3470
East Asian (EAS)
AF:
0.878
AC:
4545
AN:
5176
South Asian (SAS)
AF:
0.679
AC:
3278
AN:
4826
European-Finnish (FIN)
AF:
0.628
AC:
6639
AN:
10564
Middle Eastern (MID)
AF:
0.548
AC:
161
AN:
294
European-Non Finnish (NFE)
AF:
0.597
AC:
40590
AN:
67976
Other (OTH)
AF:
0.665
AC:
1405
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1561
3122
4684
6245
7806
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
806
1612
2418
3224
4030
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.610
Hom.:
19483
Bravo
AF:
0.700
Asia WGS
AF:
0.773
AC:
2687
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:14
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Mucopolysaccharidosis, MPS-III-D Benign:6
-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Sep 21, 2015
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jul 01, 2021
Pars Genome Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Aug 10, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

not provided Benign:4
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Dec 04, 2016
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: The c.198G>A (p.Pro66=) in GNS gene is a synonymous change that involves a non-conserved nucleotide. 5/5 programs in Alamut predict that this variant does not affect normal splicing, however no functional studies supporting this notion were published at the time of evaluation. The variant is present in the control population dataset of ExAC at a frequency of 0.0655 (75159/114750 chrs tested), indicating that it is an ancestral allele. The observed frequency exceeds the maximum expected allele frequency for a pathogenic GNS variant of 0.0011 suggesting that it is a benign polymorphism. The variant of interest has been reported as Benign by a reputable database/clinical laboratory. Taking together, based on the prevalence in general population the variant was classified as Benign. -

Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Oct 20, 2015
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

not specified Benign:3
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jun 03, 2014
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Clinical Genetics, Academic Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Sanfilippo syndrome Benign:1
Sep 16, 2020
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.43
CADD
Benign
8.7
DANN
Benign
0.48
PhyloP100
-0.44
PromoterAI
-0.016
Neutral
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Mutation Taster
=98/2
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
Splicevardb
1.0
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1147096; hg19: chr12-65146532; COSMIC: COSV108044179; API